HRS-9531
- Generic Name
- HRS-9531
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Phase 3
Not yet recruiting
- Conditions
- Bstructive Sleep Apnea (OSA) and Obesity
- Interventions
- Drug: HRS9531placebo
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06974851
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06792955
- Locations
- 🇨🇳
Central Hospital Affiliated To Shandong First Medical University, Jinan, Shandong, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Overweight or Obesity
- Interventions
- Drug: HRS-4729 injectionDrug: HRS-4729 injection placeboDrug: HRS9531 injection placebo
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 103
- Registration Number
- NCT06762600
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT06723691
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06654960
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
Phase 3
Recruiting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: HRS9531 Placebo Injection
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT06650007
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 840
- Registration Number
- NCT06649344
- Locations
- 🇨🇳
Zhu Xianyi Memorial Hospital,Tianjin Medical University, Tianjin, Tianjin, China
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome
Phase 2
Not yet recruiting
- Conditions
- Obese Subjects With Polycystic Ovary Syndrome (PCOS)
- Interventions
- Drug: HRS9531placebo
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT06595797
A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea
Phase 2
Not yet recruiting
- Conditions
- Weight Management
- Interventions
- Drug: Placebo Injection
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT06565871
A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Overweight or Obesity; Type 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT06435676
- Locations
- 🇨🇳
The Second Hospital Of Anhui medical University, Hefei, Anhui, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath